UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October, 2024.

 

Commission File Number: 001-39530

 

 

ImmunoPrecise Antibodies Ltd.

3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

 

 


 

 

EXHIBIT INDEX

 

 

Exhibit

Description

99.1

Press Release dated October 21, 2024

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

IMMUNOPRECISE ANTIBODIES LTD.

Date: October 21, 2024

 

 

 

 

 

By:

/s/ Kristin Taylor

 

Name:

Kristin Taylor

 

Title:

Chief Financial Officer

 

 


ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

 



VICTORIA, BRITISH COLUMBIA (CANADA), October 21, 2024ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024.

 

AI Driven Drug Discovery Summit

Date: Thursday, November 14

Time: 11:30pm EST

Format: Fireside Chat

To register for the event, please click here

Meet with Us

For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com , +1.917.214.3514.

 

About ImmunoPrecise Antibodies Ltd.

 

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

 

Investor Relations Contact

 

Kirsten Beduya

Quantum Media Group, LLC

kirsten@quantum-corp.com

 

Source: ImmunoPrecise Antibodies Ltd.



ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 10 2024 まで 10 2024 ImmunoPrecise Antibodiesのチャートをもっと見るにはこちらをクリック
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 10 2023 まで 10 2024 ImmunoPrecise Antibodiesのチャートをもっと見るにはこちらをクリック